AGP Executive Report
Last update: 2 hours agoClinical CBD Update: A Phase II trial reports oral CBD (twice daily) reduced pericarditis pain and recurrence in recurrent cases, with many patients staying recurrence-free during an extension period. Medical Cannabis Reimbursement: Colorado’s workers’ comp pilot suggests reimbursing medical cannabis may improve outcomes and help some patients voluntarily cut opioid use. Regulatory Crackdown (Virginia): Attorney General Jay Jones announced a Regulated Products Enforcement Unit to oversee enforcement and compliance for liquid nicotine vapes, THC/hemp products, and kratom. Hemp/THC Rules Tighten (Texas): Texas is banning most hemp-derived THC products (including delta-8/delta-10) effective July 31, while delta-9 remains legal. Local Market Moves (Canada): High Tide completed its Northern Helm acquisition, adding four Ontario retail cannabis stores and expanding its Canadian footprint. Product Clarity (CBD/THC): A new explainer breaks down live resin vs live rosin vs distillate for shoppers comparing flavor, potency, and price. Real-World Use Research: Observational data links THC-infused edibles with lower lower-back-pain intensity on use days, while CBD-dominant products showed no similar effect.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
